Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea
· Delayed Price · Currency is KRW 1,773.00
-24.00 (-1.34%)
Apr 29, 2026, 3:30 PM KST
Xcell Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Operating Revenue | 1,949 | 1,934 | 1,124 | 1,020 | 1,966 | Upgrade
|
| Other Revenue | - | - | - | 0 | - | Upgrade
|
| Revenue | 1,949 | 1,934 | 1,124 | 1,020 | 1,966 | Upgrade
|
| Revenue Growth (YoY) | 0.76% | 72.11% | 10.18% | -48.12% | 264.00% | Upgrade
|
| Cost of Revenue | 3,915 | 3,333 | 2,987 | 2,773 | 2,284 | Upgrade
|
| Gross Profit | -1,966 | -1,399 | -1,863 | -1,753 | -318.08 | Upgrade
|
| Selling, General & Admin | 5,463 | 4,323 | 3,400 | 3,219 | 3,058 | Upgrade
|
| Research & Development | 2,576 | 2,728 | 2,753 | 2,596 | 1,832 | Upgrade
|
| Amortization of Goodwill & Intangibles | 108.25 | 53.23 | 53.83 | 73.48 | 56.2 | Upgrade
|
| Other Operating Expenses | 38.81 | 36.01 | 71.45 | 140.21 | 78.1 | Upgrade
|
| Operating Expenses | 8,886 | 7,931 | 7,076 | 6,546 | 5,387 | Upgrade
|
| Operating Income | -10,852 | -9,330 | -8,939 | -8,299 | -5,705 | Upgrade
|
| Interest Expense | -3.43 | -4.4 | -3.12 | -2.89 | -179.78 | Upgrade
|
| Interest & Investment Income | 116.56 | 201.29 | 50.84 | 114.02 | 41.75 | Upgrade
|
| Earnings From Equity Investments | -0.81 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.57 | 12.84 | 2.52 | 11.57 | 2.38 | Upgrade
|
| Other Non Operating Income (Expenses) | -304.76 | -295.6 | -257.58 | -165.59 | -3,186 | Upgrade
|
| EBT Excluding Unusual Items | -11,045 | -9,416 | -9,147 | -8,342 | -9,026 | Upgrade
|
| Gain (Loss) on Sale of Investments | 19.02 | 2.72 | -0.87 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 98.66 | -130.13 | 21 | -0.53 | -12 | Upgrade
|
| Asset Writedown | - | - | -154.12 | - | - | Upgrade
|
| Pretax Income | -10,927 | -9,543 | -9,281 | -8,342 | -9,038 | Upgrade
|
| Net Income | -10,927 | -9,543 | -9,281 | -8,342 | -9,038 | Upgrade
|
| Net Income to Common | -10,927 | -9,543 | -9,281 | -8,342 | -9,038 | Upgrade
|
| Shares Outstanding (Basic) | 12 | 10 | 9 | 9 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 10 | 9 | 9 | 8 | Upgrade
|
| Shares Change (YoY) | 16.46% | 13.11% | 1.02% | 5.71% | 364.87% | Upgrade
|
| EPS (Basic) | -938.00 | -954.00 | -1049.40 | -952.90 | -1091.40 | Upgrade
|
| EPS (Diluted) | -938.00 | -954.00 | -1049.40 | -953.00 | -1091.40 | Upgrade
|
| Free Cash Flow | -10,369 | -7,379 | -7,008 | -8,475 | -5,952 | Upgrade
|
| Free Cash Flow Per Share | -890.07 | -737.67 | -792.48 | -968.02 | -718.67 | Upgrade
|
| Gross Margin | -100.87% | -72.30% | -165.77% | -171.89% | -16.18% | Upgrade
|
| Operating Margin | -556.79% | -482.33% | -795.37% | -813.59% | -290.14% | Upgrade
|
| Profit Margin | -560.65% | -493.36% | -825.74% | -817.85% | -459.67% | Upgrade
|
| Free Cash Flow Margin | -532.01% | -381.48% | -623.58% | -830.82% | -302.69% | Upgrade
|
| EBITDA | -9,148 | -7,677 | -7,341 | -6,786 | -4,686 | Upgrade
|
| EBITDA Margin | - | - | - | - | -238.34% | Upgrade
|
| D&A For EBITDA | 1,704 | 1,653 | 1,598 | 1,513 | 1,019 | Upgrade
|
| EBIT | -10,852 | -9,330 | -8,939 | -8,299 | -5,705 | Upgrade
|
| EBIT Margin | - | - | - | - | -290.14% | Upgrade
|
| Advertising Expenses | 315.64 | 154.72 | 315.24 | 267.87 | 279.25 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.